Wondering if Pfizer is quietly turning into a value opportunity, or if the market is still too skeptical, you are not alone.

Wondering if Pfizer is a smart buy at today's price? You are not alone, especially as value-focused investors begin to focus on the stock. Pfizer's performance has been mixed lately. Shares dipped ...

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

Pfizer possesses several qualities that make it attractive when market volatility is high. The stock has a low forward ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

Within Pfizer’s large product portfolio, several mixed product trends led to overall 4% year-over-year growth, with particularly strong sales in vaccines and cancer drugs offsetting declines from ...

Pfizer (PFE) shares have shown some movement this week, drawing attention for investors evaluating the company’s current ...

Pfizer (NYSE: PFE) has been around for 175 years, selling a wide range of drugs in various treatment areas over time. But this pharma giant truly became a household name a few years ago. Pfizer made ...

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

ALEXANDRIA, VA (June 17, 1999)-- Pfizer (NYSE: PFE) is trading at 38 times its trailing 12-month earnings per share, 40 times 1999 estimates, and 33.9 times the year 2000 EPS guess. The largest ...